Trial Profile
Assessment of Dose-Dependent Effects of LY2189265 on Glycemic Control in Patients With Type 2 Diabetes Treated Only With Lifestyle Interventions.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Dulaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 06 Nov 2012 Planned number of patients changed from 180 to 225.
- 18 Jul 2012 Results published in the Diabetic Medicine.
- 16 Sep 2011 Results presented at the 47th Annual Meeting of the European Association for the Study of Diabetes.